BioAtla, Inc. develops Conditionally Active Biologic (CAB) antibody therapeutics for solid-tumor cancers. News about BCAB centers on clinical and regulatory updates for its antibody-drug conjugate, T-cell engager and bispecific programs, including mecbotamab vedotin (Mec-V), ozuriftamab vedotin, evalstotug, BA3182 and CAB-Nectin4 programs.
Company updates also cover operating results, financing agreements, license milestones, cost-containment actions, strategic-review disclosures, Nasdaq listing matters, shareholder votes and capital-structure changes tied to BioAtla's common stock and preferred-stock authorizations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.